Selection of Patients with Monoclonal Grammopathy of Undetermined Significance is Mandatory for a Reliable Use of lnterleukin-6 and Other Nonspecific Multiple Myeloma Serum Markers
Selection of Patients with Monoclonal Grammopathy of Undetermined Significance is Mandatory for a...
Greco, Claudia; Ameglio, Franco; Alvino, Silvana; Cianciulli, Anna Maria; Giovannelli, Maurizio; Mattei, Fabrizio; Vitelli, Gaetano; Venturo, Irene; Lopez, Massimo; Gandolfo, Giuseppe Maria
1994-01-01 00:00:00
Serum levels of various immunochémical markers of clinical interest, as interleukin-6 (IL-6), C-reactive protein (CRP) and β<sub>2</sub>-microglobulin (β<sub>2</sub>M), were measured in sera from 98 subjects affected with monoclonal gammopathy of undetermined significance (MGUS; 80% of which bearing cancer too) and from 39 patients with multiple myeloma (MM). In addition, the ratio between serum IgG/IgA amounts (GAR) was also calculated in monoclonal gammopathies of IgG type. Consistent with our previous investigations, we found that tumor presence significantly influenced the serum levels of the various markers (except GAR) in MGUS patients; in fact, only when comparing MGUS without tumor and MM patients, was a clear difference observed for all markers considered. The data presented discourage the use of IL-6, CRP and β<sub>2</sub>M as discriminant indices between MGUS and MM patients, unless a careful selection of MGUS subjects is performed. Further investigations on these potential markers are therefore needed for a more rational clinical application.
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngActa HaematologicaKargerhttp://www.deepdyve.com/lp/karger/selection-of-patients-with-monoclonal-grammopathy-of-undetermined-9ygceMc36s
Selection of Patients with Monoclonal Grammopathy of Undetermined Significance is Mandatory for a Reliable Use of lnterleukin-6 and Other Nonspecific Multiple Myeloma Serum Markers
Serum levels of various immunochémical markers of clinical interest, as interleukin-6 (IL-6), C-reactive protein (CRP) and β<sub>2</sub>-microglobulin (β<sub>2</sub>M), were measured in sera from 98 subjects affected with monoclonal gammopathy of undetermined significance (MGUS; 80% of which bearing cancer too) and from 39 patients with multiple myeloma (MM). In addition, the ratio between serum IgG/IgA amounts (GAR) was also calculated in monoclonal gammopathies of IgG type. Consistent with our previous investigations, we found that tumor presence significantly influenced the serum levels of the various markers (except GAR) in MGUS patients; in fact, only when comparing MGUS without tumor and MM patients, was a clear difference observed for all markers considered. The data presented discourage the use of IL-6, CRP and β<sub>2</sub>M as discriminant indices between MGUS and MM patients, unless a careful selection of MGUS subjects is performed. Further investigations on these potential markers are therefore needed for a more rational clinical application.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.